Ds-8201: best use of HER2?

Azn and Sangong announced the second phase clinical results of their HER2 ADC drug, trastuzumab deluxtecan (ds-8201), called destiny-breast01, at the SABCS annual meeting today In this single arm trial, 184 HER2 positive breast cancer patients were recruited who were resistant to her drugs, including kadcyla, a Roche ADC drug Results 8201 patients with 6 treatments failed on average had 61% response rate, and 11 of them had complete response The median response time was 14.8 months and PFS was 16.4 months This data is basically consistent with the 60% response rate of phase I clinical, which is 2-3 times of the historical data Although 14% of patients have lung injury, experts estimate that even with this black box warning, it will not affect the use of the product The peak sales of this product are expected to reach US $4.5 billion HER2 is one of the earliest solid tumor targets, Herceptin is one of the earliest antibody drugs and one of the most successful solid tumor drugs After Herceptin, perjeta, HER2 / HER3 dimer inhibitor, kadcyla, and margeuximab, which was recently improved by FC, were successively listed, or showed better efficacy than Herceptin or showed the efficacy of Herceptin resistance HER2 bispecific antibody zw25 showed remarkable early therapeutic effect in many HER2 positive solid tumors other than breast cancer Obviously, the best way to use HER2 is still under exploration There is still room for optimization of which killing weapon to use and how to selectively enter HER2 cells These follow-up drugs will also make HER2, the old target, continue to improve the survival of patients and continue to make a lot of profits for manufacturers.